TCGA-86-6851-01A-11R-1949-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- INTERFERON_GAMMA_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.440
- IL6_JAK_STAT3_SIGNALING+0.400
- COMPLEMENT+0.250
- MITOTIC_SPINDLE+0.240
- IL2_STAT5_SIGNALING+0.210
- INFLAMMATORY_RESPONSE+0.140
- HEME_METABOLISM+0.130
- PI3K_AKT_MTOR_SIGNALING+0.110
Top 10 suppressed
- MYC_TARGETS_V2-0.580
- MYC_TARGETS_V1-0.540
- OXIDATIVE_PHOSPHORYLATION-0.490
- E2F_TARGETS-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- PANCREAS_BETA_CELLS-0.380
- ADIPOGENESIS-0.350
- CHOLESTEROL_HOMEOSTASIS-0.350
- G2M_CHECKPOINT-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | be8d8236-4ebc-46de-a4fd-a901fec1cdce | — | — | 0.892 |
| 2 | TCGA-22-1005-01A-01R-A96U-41 | — | cohortMD2 | 0.888 |
| 3 | BS_25T139TX | low-grade glioma | — | 0.860 |
| 4 | SRR25043622 | — | — | 0.859 |
| 5 | SRR8613700 | — | D | 0.855 |
| 6 | SRR6013560 | — | cohortMD2 | 0.851 |
| 7 | SRR1313132 | — | D | 0.851 |
| 8 | BS_J6VKB1VE | low-grade glioma | — | 0.840 |
| 9 | 30608f63-2604-489c-bf96-09e56acfe912 | — | — | 0.839 |
| 10 | GSM5359433 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |